LobbyingWuxi Biologics USA lobbying by quarter
Wuxi Biologics USA's latest lobbying report covers Q2 2026, at $170K. The four quarters Q4 2025–Q3 2026 total $520K. Its first report covers Q3 2023; the issues it reports most are Health Issues and Economics/Economic Development.
Wuxi Biologics USA
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $520K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q3 2023
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q3 2023 | $40K | 1 |
| Q4 2023 | $40K | 1 |
| Q1 2024 | $40K | 1 |
| Q2 2024 | $165K | 2 |
| Q3 2024 | $140K | 2 |
| Q4 2024 | $110K | 2 |
| Q1 2025 | $190K | 2 |
| Q2 2025 | $190K | 2 |
| Q3 2025 | $180K | 2 |
| Q4 2025 | $180K | 2 |
| Q1 2026 | $170K | 2 |
| Q2 2026 | $170K | 2 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$1.3M · 21 reports
- Economic development$340K · 12 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES21 reports
- SENATE21 reports
- Health & Human Services, Dept of (HHS)13 reports
- Commerce, Dept of (DOC)10 reports
- Defense, Dept of (DOD)10 reports
- Treasury, Dept of10 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseWuxi Biologics USA | $935K | 9 quarters |
| FGS Global | $680K | 12 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | In-house | $100K |
| 07/16for Q2 | FGS Global | $70K |
| 04/14for Q1 | FGS Global | $70K |
| 04/10for Q1 | In-house | $100K |
| 01/20for Q4 2025 | In-house | $110K |
| 01/20for Q4 2025 | FGS Global | $70K |
| 25/10/17for Q3 2025 | In-house | $100K |
| 25/10/15for Q3 2025 | FGS Global | $80K |
| 25/07/21for Q2 2025 | In-house | $110K |
| 25/07/16for Q2 2025 | FGS Global | $80K |
| 25/04/18for Q1 2025 | In-house | $120K |
| 25/04/15for Q1 2025 | FGS Global | $70K |
| 25/01/17for Q4 2024 | In-house | $70K |
| 25/01/15for Q4 2024 | FGS Global | $40K |
| 24/10/21for Q3 2024 | In-house | $100K |
| 24/10/17for Q3 2024 | FGS Global | $40K |
| 24/07/22for Q2 2024 | In-house | $125K |
| 24/07/09for Q2 2024 | FGS Global | $40K |
| 24/05/14for Q2 2024 | In-house | Under $5,000 |
| 24/04/22for Q1 2024 | FGS Global | $40K |